News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
GoodRx Holdings, Inc. - Class A Common Stock
(NQ:
GDRX
)
2.290
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about GoodRx Holdings, Inc. - Class A Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
20
21
Next >
Amazon Is Now Offering Novo Nordisk's Wegovy Pill in Its Pharmacy. Here's How That Could Affect Hims & Hers, WW International, and GoodRx Holdings.
↗
February 05, 2026
There's another fight brewing around GLP-1 drugs -- this time on the delivery side.
Via
The Motley Fool
GoodRx Powers Pricing for Leading Brand Medications on TrumpRx
February 05, 2026
From
GoodRx
Via
Business Wire
1 Oversold Stock Set for a Comeback and 2 We Brush Off
February 04, 2026
Hitting a new 52-week low can be a pivotal moment for any stock. These floors often mark either the beginning of a turnaround story or confirmation that a company faces serious headwinds.
Via
StockStory
GoodRx Earns HITRUST i1 Certification for the Second Consecutive Year, Reinforcing Its Commitment to Protecting Healthcare Data at Scale
February 02, 2026
From
GoodRx
Via
Business Wire
1 Stock Under $10 to Target This Week and 2 Facing Headwinds
February 01, 2026
Investors can certainly boost their returns by concentrating on stocks trading between $1 and $10. However, a disciplined approach is necessary because many of these businesses are speculative and lack...
Via
StockStory
1 of Wall Street’s Favorite Stock to Target This Week and 2 We Question
January 29, 2026
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional...
Via
StockStory
GoodRx Announces Date for Fourth Quarter and Full Year 2025 Earnings Release and Conference Call
January 28, 2026
From
GoodRx Holdings, Inc.
Via
Business Wire
Q3 Earnings Highlights: GoodRx (NASDAQ:GDRX) Vs The Rest Of The Healthcare Technology Stocks
January 25, 2026
Wrapping up Q3 earnings, we look at the numbers and key takeaways for the healthcare technology stocks, including GoodRx (NASDAQ:GDRX) and its peers.
Via
StockStory
Surescripts and GoodRx Partner to Advance Patient Price Transparency
January 13, 2026
From
Surescripts
Via
Business Wire
GoodRx Launches RxSmartSaver at Giant Eagle Pharmacies
January 08, 2026
From
GoodRx
Via
Business Wire
Hims & Hers Enters 2026 On Solid Ground — Stock Rises Even After Novo Nordisk Leaves It Off Wegovy Partner List
↗
January 05, 2026
The development comes as attention remains on Hims’ longer-term business expansion initiatives.
Via
Stocktwits
GoodRx Now Offers Novo Nordisk’s Cash Price for the Launch of the Wegovy® Pill
January 05, 2026
From
GoodRx
Via
Business Wire
1 Cash-Producing Stock to Keep an Eye On and 2 We Avoid
December 31, 2025
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Via
StockStory
1 Value Stock to Target This Week and 2 Facing Headwinds
December 28, 2025
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued...
Via
StockStory
3 Healthcare Stocks We Approach with Caution
December 18, 2025
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have...
Via
StockStory
Topics
Stocks
GoodRx to Participate in the 44th Annual J.P. Morgan Healthcare Conference
December 16, 2025
From
GoodRx Holdings, Inc.
Via
Business Wire
3 Stocks Under $10 That Fall Short
December 09, 2025
Investors can certainly boost their returns by concentrating on stocks trading between $1 and $10. However, a disciplined approach is necessary because many of these businesses are speculative and lack...
Via
StockStory
Why GoodRx (GDRX) Stock Is Trading Lower Today
December 09, 2025
Shares of healthcare tech company GoodRx (NASDAQ:GDRX) fell 1.7% in the afternoon session after Barclays initiated coverage on the health-focused technology company with an "Underweight" rating and a...
Via
StockStory
Topics
Government
1 Profitable Stock Worth Your Attention and 2 We Turn Down
December 04, 2025
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
Via
StockStory
Natera, GoodRx, and Bio-Techne Shares Are Soaring, What You Need To Know
November 24, 2025
A number of stocks jumped in the afternoon session after reports revealed the Trump administration considered extending the Affordable Care Act (ACA) subsidies.
Via
StockStory
Topics
Economy
Government
Clover Health, GoodRx, Moderna, UFP Technologies, and Masimo Shares Are Soaring, What You Need To Know
November 21, 2025
A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated...
Via
StockStory
Topics
Economy
3 Small-Cap Stocks That Fall Short
November 19, 2025
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside...
Via
StockStory
Novo Nordisk Leans Into Affordability Amid Rising Competition
↗
November 17, 2025
Novo Nordisk offers limited-time $199 pricing on Wegovy and Ozempic, lowers self-pay costs, and prepares for a stronger Wegovy pill rollout.
Via
Benzinga
GoodRx Launches New $39 Per Month Weight Loss Telemedicine Subscription, Unveils Industry-Leading Introductory Cash Price of $199 Per Month for Ozempic® and Wegovy®
November 17, 2025
From
GoodRx
Via
Business Wire
5 Revealing Analyst Questions From GoodRx’s Q3 Earnings Call
November 11, 2025
GoodRx’s third quarter results were met with a moderate positive market response, as the company’s revenue modestly exceeded Wall Street expectations despite being flat year-over-year. Management...
Via
StockStory
Topics
Earnings
3 Value Stocks We Find Risky
November 09, 2025
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few...
Via
StockStory
3 Low-Volatility Stocks with Open Questions
November 05, 2025
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
Via
StockStory
GDRX Q3 Deep Dive: Manufacturer Solutions Growth Offsets Flat Prescription Volumes
November 05, 2025
Healthcare tech company GoodRx (NASDAQ:GDRX) reported revenue ahead of Wall Streets expectations in Q3 CY2025, but sales were flat year on year at $196 million. Its non-GAAP profit of $0.08 per share...
Via
StockStory
GoodRx’s (NASDAQ:GDRX) Q3 Sales Top Estimates
November 04, 2025
Healthcare tech company GoodRx (NASDAQ:GDRX) reported Q3 CY2025 results exceeding the market’s revenue expectations, but sales were flat year on year at $196 million. Its non-GAAP profit of $0.08 per...
Via
StockStory
GoodRx Reports Third Quarter 2025 Results
November 04, 2025
From
GoodRx Holdings, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
20
21
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.